Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19

被引：35
|
作者：
Giovannoni, Gavin [1 ]
机构：
[1] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2020年 / 41卷
关键词：
OCRELIZUMAB;
D O I：
10.1016/j.msard.2020.102135
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Response to COVID-19 mRNA Vaccination in Patients with Multiple Sclerosis on anti-CD20 Disease Modifying Therapies
    Wolf, Andrew
    Pratt, Robert W.
    Crooks, Kristy
    Borko, Tyler
    Gonzalez, Jose Parra
    Vollmer, Timothy
    Frazer-Abel, Ashley
    ANNALS OF NEUROLOGY, 2021, 90 : S179 - S180
  • [2] COVID-19 and MS disease-modifying therapies
    Berger, Joseph R.
    Brandstadter, Rachel
    Bar-Or, Amit
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (04):
  • [3] Anti-CD20 disease modifying therapies decrease the humoral response to COVID-19 mRNA vaccination in patients with multiple sclerosis
    Wolf, A.
    Pratt, R.
    Crooks, K.
    Borko, T.
    Gonzalez, J. Parra
    Vollmer, T.
    Frazer-Abel, A.
    Alvarez, E.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 581 - 581
  • [4] COVID-19 vaccines and multiple sclerosis disease-modifying therapies
    Giovannoni, Gavin
    Hawkes, Christopher H.
    Lechner-Scott, Jeannette
    Levy, Michael
    Yeh, E. Ann
    Baker, David
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 53
  • [5] The COVID-19 pandemic and the use of MS disease-modifying therapies
    Giovannoni, Gavin
    Hawkes, Chris
    Lechner-Scott, Jeannette
    Levy, Michael
    Waubant, Emmanuelle
    Gold, Julian
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
  • [6] Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era
    Ciotti, John R.
    Grebenciucova, Elena
    Moss, Brandon P.
    Newsome, Scott D.
    ANNALS OF NEUROLOGY, 2020, 88 (06) : 1062 - 1064
  • [7] COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
    Meca-Lallana, Virginia
    Aguirre, Clara
    Rio, Beatrizdel
    Cardenoso, Laura
    Alarcon, Teresa
    Vivancos, Jose
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 44
  • [8] Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown
    Zrzavy, T.
    Wimmer, I
    Rommer, P. S.
    Berger, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (10) : 3503 - 3516
  • [9] COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
    Reder, Anthony T.
    Centonze, Diego
    Naylor, Maria L.
    Nagpal, Anjali
    Rajbhandari, Rajani
    Altincatal, Arman
    Kim, Michelle
    Berdofe, Aaron
    Radhakrishnan, Maha
    Jung, Eunice
    Sandrock, Alfred W.
    Smirnakis, Karen
    Popescu, Catrinel
    de Moor, Carl
    CNS DRUGS, 2021, 35 (03) : 317 - 330
  • [10] Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
    Simpson-Yap, Steve
    De Brouwer, Edward
    Kalincik, Tomas
    Rijke, Nick
    Hillert, Jan A.
    Walton, Clare
    Edan, Gilles
    Moreau, Yves
    Spelman, Tim
    Geys, Lotte
    Parciak, Tina
    Gautrais, Clement
    Lazovski, Nikola
    Pirmani, Ashkan
    Ardeshirdavanai, Amin
    Forsberg, Lars
    Glaser, Anna
    McBurney, Robert
    Schmidt, Hollie
    Bergmann, Arnfin B.
    Braune, Stefan
    Stahmann, Alexander
    Middleton, Rodden
    Salter, Amber
    Fox, Robert J.
    van der Walt, Anneke
    Butzkueven, Helmut
    Alroughani, Raed
    Ozakbas, Serkan
    Rojas, Juan, I
    van der Mei, Ingrid
    Nag, Nupur
    Ivanov, Rumen
    do Olival, Guilherme Sciascia
    Dias, Alice Estavo
    Magyari, Melinda
    Brum, Doralina
    Mendes, Maria Fernanda
    Alonso, Ricardo N.
    Nicholas, Richard S.
    Bauer, Johana
    Chertcoff, Anibal Sebastian
    Zabalza, Anna
    Arrambide, Georgina
    Fidao, Alexander
    Comi, Giancarlo
    Peeters, Liesbet
    NEUROLOGY, 2021, 97 (19) : E1870 - E1885
12345